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Abstract 
The inflammatory bowel diseases (IBD) Crohn's disease and ulcerative colitis are common causes of morbidity 
in children and young adults in the western world. Here we report the results of a genome-wide association study 
in early-onset IBD involving 3,426 affected individuals and 11,963 genetically matched controls recruited 
through international collaborations in Europe and North America, thereby extending the results from a previous 
study of 1,011 individuals with early-onset IBD1. We have identified five new regions associated with early-
onset IBD susceptibility, including 16p11 near the cytokine gene IL27 (rs8049439, P = 2.41 × 10-9), 22q12 
(rs2412973, P = 1.55 × 10-9), 10q22 (rs1250550, P= 5.63 × 10-9), 2q37 (rs4676410, P= 3.64 × 10-8) and 
19q13.11 (rs10500264, P= 4.26 × 10-10). Our scan also detected associations at 23 of 32 loci previously 
implicated in adult-onset Crohn's disease and at 8 of 17 loci implicated in adult-onset ulcerative colitis, 
highlighting the close pathogenetic relationship between early- and adult-onset IBD. 
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Crohn's disease and ulcerative colitis are chronic inflammatory disorders of the gastrointestinal tract that most 
commonly arise during the second and third decades of life. Incidence, family, twin and phenotype concordance 
studies suggest that IBD is highly heritable, albeit complex, spurring an ongoing search for genetic factors that 
confer susceptibility to this disease2,3. Genome-wide association studies (GWASs) applying high-density SNP 
array technology have greatly expanded the number of genetic factors implicated in IBD pathogenesis to include 
32 loci associated with Crohn's disease and 17 associated with ulcerative colitis, spanning pathways involved in 
adaptive (IL23R, IL10, IL12B, STAT3) and innate (CARD15, ATG16L1,IRGM) immunity4-7. 
Most genetic analyses in IBD have been performed in adult-onset disease2,3. Early-onset IBD, however, has 
unique characteristics of phenotype, severity and familiality8,9, features that provide support for the search for 
loci that may be specific to early-onset disease. In addition, because early-onset IBD has a stronger familial 
component than the adult disease, studies targeting this subgroup potentially provide additional power to identify 
genes that contribute modest effects, as illustrated by the success of our previous scan in identifying 20ql3 and 
21q22 as IBD loci1. 
We now report results from the largest GWAS conducted so far in early-onset IBD (Fig. 1). Our IBD discovery 
cohort (DC-IBD) comprised 2,413 individuals of European ancestry with IBD (cases), including 1,636 with 
Crohn's disease (DC-CD), 724 with ulcerative colitis (DC-UC) and 53 with IBD of unclassified type (IBD-U), 
and 6,158 genetically matched controls, and was genotyped on the Illumina HumanHap550 platform. Affected 
individuals were recruited from multiple centers from four geographically discrete countries and diagnosed 
before their nineteenth birthday according to standard IBD diagnostic criteria (Supplementary Table 1). Our 
study extends a previous IBD GWAS that was based on a subset of these cases (1,011 IBD cases, including 647 
with Crohn's disease, 317 with ulcerative colitis and 47 with IBD-U; Supplementary Table 2)1. An independent 
replication cohort (RC1) of 482 early-onset IBD cases (289 with Crohn's disease, 120 with ulcerative colitis and 
73 with IBD-U) and 1,696 genetically matched controls was gathered from the Children's Hospital of 
Philadelphia (CHOP) health system and collaborating centers. We refer to Crohn's disease and ulcerative colitis 
subanalyses of data set RC1 as RC1-CD and RCl-UC, respectively. A second replication cohort (RC2-CD) of 
531 Crohn's disease cases diagnosed in childhood and 4,109 controls was assembled by the International IBD 
Genetics Consortium (IIBDGC). This cohort is based on subsets of data from genome-wide scans generated by 
the US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)10, the Wellcome Trust Case 
Control Consortium (WTCCC)11 and a Belgian-French12 collaboration, which have been combined previously in 
a large-scale meta-analysis5. We computed P values in each cohort by comparing single-marker allele 
frequencies using χ2 statistics on SNPs that passed quality-control criteria. We conducted meta-analysis across 
multiple studies using a Z-score transformation. See Online Methods for more detailed descriptions of cohorts 
and methods used in this study. 
We first searched for previously unreported signals, including loci that met stringent genome-wide significant (P 
< 5 × 10-8) and suggestive (P < 1 × 10 -6) thresholds in our three discovery scans (DC-CD, DC-UC and DC-
IBD). For confirmation of these loci, we sought evidence for replication in two independent early-onset cohorts 
(RC1 and RC2-CD). Lastly, we combined our discovery and replication cohorts for Crohn's disease (Table 1), 
ulcerative colitis (Table 2) and IBD (Table 3) in a meta-analysis. 
Analysis of DC-CD identified a region on 16p11 as the single new genome-wide significant locus; the most 
significant SNP in the block of linkage disequilibrium (LD) containing this locus, rsl968752, yielded a value of 
P = 2.09 × 10-8, with the minor allele (A) conferring risk (odds ratio (OR) = 1.25 (1.16-1.36)). We observed 
nominal replication of rsl968752 in the RC2-CD data set (P = 0.036, OR = 1.09 (0.94-1.27)) and a trend for 
association in the combined analysis of the replication cohorts (RC1-CD and RC2-CD), using two-sided P values 
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Figure 1 Overview of genome-wide association results, (a-c) Chromosomal plots of-logP against genomic 
location for discovery scans in the early-onset DC-CD (a), DC-UC (b) and DC-IBD (c) cohorts. Red and blue dotted 
lines represent thresholds for genome-wide significant (P = 1 × 10-7) and suggestive (P = 1 × 10-6) signals, respectively. Loci on 16p11, 
22q12 and 2q37 emerged from these analyses as suggestive signals and were validated in the follow-up cohorts RC1 and RC2-CD. The 
following signals did not replicate or show significance in the meta-analysis: lq22 (CD), 10q25 (UC), 16q21 (UC), 18ql2 (UC), 8q24 (IBD) 
and 15q22 (IBD). The remaining loci have been previously identified in majority adult-onset genome scans of Crohn's disease and ulcerative 
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Table 1 Newly discovered loci significant in the GWAS of the DC-CD, RC1-CD and RC2-CD cohorts 
 CD discovery (DC-CD) 
(n = 1,636/6,158) 
CHOP CD replication (RC1-CD) 
(n = 289/ 1,696) 
IIBDGC replication (RC2-CD) 
(n = 531 /4,109) 
Combined 
(n = 2,456/11,963) 
Band (Mb) Genes SNP Allele P MAFA MAFU OR [95% CI] P MAFA MAFU OR [95% CI] P MAFA MAFIJ OR [95% CI] P Z 
10q22.3 ZMIZ1 rS1250550 A/T 1.59E-05 0.28 0.32 0.83 0.001 0.28 0.35 0.73 0.005 0.20 0.24 0.82 4.41E-10 -6.24 
(80.71-80.73)       [0.76-0.90]    [0.60-0.88]    [0.70-0.96]   




     [1.13-1.32]    [0.92-1.32]    [1.00-1.30]   
22q12.2 H0RMAD2, rS2412973 A/T 6.16E-06 0.50 0.46 1.19 0.0095 0.52 0.46 1.26 0.0160 0.50 0.46 1.15 3.77E-08 5.50 
(28.75-28.86) MTMR3, 
LIF 
     [1.10-1.29]    [1.06-1.51]    [1.01-1.31]   
MAF, minor allele frequency. 
 
Table 2 Newly discovered loci significant in the GWAS of the DC-UC and RC1-UC cohorts 
 UC discovery (DC-UC) 
(n = 724/6,158) 
CHOP UC replication (RC1-UC) 
(n = 120/1,696) 
Combined 
(n = 844 / 7,854) 
Band (Mb) Genes SNP Allele P MAFA MAFU OR [95% 
CI] 
P MAFA MAFU OR [95% CI] P Z 










Published in : Nature Genetics (2009) 
Status : Postprint (Author’s version) 
Table 3 Newly discovered loci significant in the GWAS of the DC-IBD, RC1 and RC2-CD cohorts 
 IBD discovery (DC-IBD)  
(n =2,413/6,158) 
CHOP IBD replication (RC1-IBD)  
(n = 482/1,696) 
IIBDGC replication (RC2-CD)  
(n = 531 /4,109) 
Combined  
(n = 3,426/11,963) 
Band (Mb) Genes SNP Allele P MAFA MAFU OR [95% CI] P MAFA MAFU OR [95% CI] P MAFA MAFU OR [95% CI] P Z 
19ql3.11  rsl0500264 A/T 1.18E-05 0.21 0.18 1.21 0.0034 0.22 0.18 1.30 0.000
64 
0.12 0.12 1.08 4.26E-10 6.24 
(38.44-38.45)       [1.11-1.31]    [1.07-1.58]    [0.89-1.31]   
22ql2.2 H0RMAD2, rs2412973 A/T 9.14E-07 0.50 0.46 1.18 0.0052 0.51 0.46 1.23 0.016 0.50 0.46 1.15 1.55E-09 6.04 
(28.75-28.86) MTMR3, 
LIP 
     [1.11-1.26]    [1.05-1.43]    [1.01-1.31]   
16p11.2 IL27, rs8049439 C/G 2.38E-07 0.41 0.37 1.20 0.34 0.40 0.38 1.08 0.001
4 




     [1.12-1.28]    [0.92-1.26]    [1.00-1.30]   
10q22.3 ZMIZ1 rsl250550 A/T 3.55E-05 0.29 0.32 0.86 0.0016 0.29 0.35 0.78 0.004
61 
0.20 0.24 0.82 5.63 E-09 -5.83 
(80.71-80.73)       [0.80-0.92]    [0.66-0.92]    [0.70-0.96]   
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Figure 2 Colonic and LCL mRNA expression of genes in significantly associated loci. The A allele of rsl968752 
confers risk in our early-onset Crohn's disease and IBD cohorts (OR = 1.23 (1.12-1.40)). rsl968752 lies in a block of LD containing the 
IL27gene. (a) Cell lines from individuals (n = 5) with the A/A genotype at rsl968752 have over 90% decrease in IL27gene expression as 
compared with those with the C/C genotype. (b) IL27colonic expression was significantly lower in samples obtained from individuals with 
early-onset Crohn's disease and ulcerative colitis cases than in normal tissue. (c,d) Expression of both SULT1A1 (c) and SULT1A2 (d) genes 
(also in the IL27 locus) was also significantly lower in Crohn's disease and ulcerative colitis tissue than in normal tissue. (e,f) Expression of 
putative IBD gene MTMR3 at 22q12 (e) and the putative ulcerative colitis gene CAPN10 at 2q37 (f) was significantly lower in ulcerative 
colitis tissue than in normal tissue. All significant expression effects were found to be independent of treatment and histological 
inflammation score (data not shown). Error bars represent s.e.m. 
 
 
Analysis of our combined IBD discovery scan yielded suggestive association at the 16pll locus (rs8049439, P = 
2.38 × 10-7, OR = 1.20 (1.12-1.28)). rs8049439 is located ~200 kb upstream of rsl968752, and the two loci are in 
strong LD (r2 = 0.796). rs8049439 showed a statistically significant association (P = 0.00144, OR= 1.14 (1.00-
1.30)) in the RC2-CD data set, whereas meta-analysis of rs8049439 in the discovery data set and the two 
replication cohorts (RC1, RC2-CD) reached genome-wide significance in both IBD (P = 2.41 × 10-9) and 
Crohn's disease (P = 2.87 × 10-9; Tables 1 and 3). In addition, analysis of the available data in a meta-analysis 
data set for adult-onset Crohn's disease5 demonstrated that an LD proxy for these two SNPs, rs4788084 (r2 = 
0.83 to rsl968752, and r2 = 0.86 to rs8049439), was also associated with Crohn's disease (P = 0.0035; 
Supplementary Table 4). Of note, we found that the risk-conferring minor allele (G) at rs8049439 shares 
haplotypes with the risk-conferring ancestral allele (A) of the type 1 diabetes SNP rs4788084 (HapMap CEU, r2 
= 0.864)13. 
The LD block incorporating rsl968752, rs8049439 and rs4788084 contains multiple genes, including IL27, 
CCDC101, CLN3, EIF3C, NUPR1, SULT1A1 and SULT1A2. Of these, we considered IL27, which encodes an 
immunomodulatory cytokine that regulates adaptive immunity responses, to be the most plausible candidate 
Published in : Nature Genetics (2009) 
Status : Postprint (Author’s version) 
gene for susceptibility to IBD. Analysis of IL27 gene expression in lym-phoblastoid cell lines (LCLs) obtained 
from ten healthy individuals homozygous for rsl968752 (that is, either A/A or C/C) showed that those 
individuals with two copies of the risk allele (A/A) had a several-fold decrease in IL27 expression relative to 
those with two copies of the nonrisk allele (C/C; P = 0.0031; Fig. 2a), suggesting that this SNP may exert a 
regulatory effect on IL27 gene expression. In addition, colonic expression of IL27 was significantly lower in 30 
individuals with early-onset Crohn's disease than in 11 healthy controls (P < 0.05; Fig. 2b). These effects 
remained significant after correction for medication use and histological inflammation score. 
When examining the colonic expression of other genes at this locus, we also detected significantly lower 
expression of SULT1A1 and SULT1A2 in both early-onset Crohn's disease (P < 0.05, P < 0.001) and ulcerative 
colitis (P < 0.0001, P < 0.0001) as compared with healthy controls (Fig.2c,d).SULT1A1and SULT1A2 encode 
sulfotransferases that catalyze sulfate conjugation of catecholamines, phenolic drugs and neurotransmitters. 
These biological functions make SULT1A1 and SULT1A2 less attractive as IBD candidate genes. We also 
observed a strongly expressed quantitative trait locus (eQTL) for EIF3C expression in LCLs at this locus (lod 
score = 5-8) on the basis of publicly available data14; however, we did not observe altered EIF3C expression in 
Crohn's disease or ulcerative colitis cases relative to healthy controls, nor did we detect an eQTL for EIF3C in 
colonic tissue at SNPs in this region (Supplementary Figs. 1 and 2). EIF3C encodes a eukaryotic translation 
initiation factor that forms part of the basic translational machinery, which also makes EIF3C less likely to be an 
IBD candidate gene. Additional allele-specific expression effects were not observed for the other genes at this 
locus either in our LCL and colonic expression data sets (Supplementary Fig. 1) or in the public database14. 
Taken together, these results point most strongly to IL27 as a candidate gene associated with early-onset IBD; 
however, further functional and fine-mapping studies are warranted to confirm this and rule out the involvement 
of other genes at this locus. 
The first of the two suggestive early-onset disease associations was identified in the DC-IBD cohort at 22ql2 
(rs2412973, P = 9.14 × 10-7, OR= 1.18 (1.10-1.26)). This SNP replicated in RC1 (P = 0.0052, OR = 1.23 (1.05-
1.43)) andRC2-CD (P = 0.016,OR = 1.15 (1.01-1.31)), yielding P = 1.55 × 10-9 in a meta-analysis across all 
three early-onset IBD cohorts (Table 3). Meta-analysis of rs2412973 across the data sets DC-CD, RC1-CD and 
RC2-CD also reached genome-wide significance (P = 3.77 × 10-8). rs2412973 also showed association in the CD 
meta-analysis data set with an age of onset primarily in adulthood5 (P = 0.000953; Supplementary Table 4). 
rs2412973 is located within HORMAD2, an open reading frame whose putative functions include mitotic 
checkpoints, chromosome synapsis and DNA repair. The LD block incorporating rs2412973 also contains 
MTMR3, encoding myo-tubularin-related protein-3, and LIF, encoding leukemia inhibitory factor, a cytokine 
that stimulates differentiation in leukocytes. We observed a significant difference in colonic MTMR3 expression 
in biopsies from individuals with ulcerative colitis as compared with controls (P < 0.001), but not in those from 
individuals with Crohn's disease (Fig. 2e), and we did not detect colonic eQTL for MTMR3 near rs2412973. 
Other genes in the LD block did not exhibit significant, expression effects (Supplementary Fig. 3). 
The second suggestive association was identified only in DC-UC at 2q37 (rs4676410, P = 1.70 × 10-7, OR 1.41 
(1.24-1.61)). This SNP showed only a trend for replication in the small RC1-UC cohort (P = 0.0611, OR = 1.38 
(1.08-1.77)), but yielded genome-wide significance in the combined analysis (P = 3.64 × 10-8; Table 2). 
rs4676410 lies within GPR35, which encodes an orphan receptor primarily expressed in the intestine of humans 
and rats. Other genes in the LD block of rs4676410 include CAPN10, KIF1A and RNPEPL1. CAPN10 colonic 
gene expression was significantly lower in ulcerative colitis cases than in controls (P < 0.05; Fig. 2f). CAPN10 
encodes a Ca2+-regulatedthiol-protease involved in cytoskeletal remodeling and signal transduction. We did not 
observe significant expression effects in the remaining genes (Supplementary Figs. 1 and 2). 
We next combined our discovery DC-IBD and replication cohorts (RC1, RC2-CD) for a genome-wide meta-
analyses of early-onset Crohn's disease, ulcerative colitis and IBD. These analyses yielded two new loci 
achieving genome-wide significance. The first new signal is associated with IBD (rsl0500264, P = 4.26 × 10-10) 
and is located at 19ql3 in a small block of LD devoid of known genes lying within 50 kb of SLC7A10 and 
CEBPA. Notably, rsl0500264 showed only nominal association in the adult-onset Crohn's disease meta-analysis 
(P = 0.0217), suggesting that this locus may be weighted more toward early-onset disease. The second new 
signal, rsl250550, lies on 10q22 inside the ZMIZ1 gene and is associated with both Crohn's disease (P = 4.41 × 
10-10) and IBD combined (P = 5.63 × 10-9; Tables 1 and 3). In addition to showing significance in the early-onset 
meta-analysis, rsl250550 robustly associates in the majority adult-onset Crohn's disease meta-analysis5 (P = 3.27 
× 10-5). ZMIZ1 encodes a PIAS-like protein that interacts with Smad4 to regulate Smad3 transcription and 
modulate transforming growth factor-β signaling15. Despite achieving robust significance in our meta-analysis, 
these loci merit replication in an independent cohort. 
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We conducted a meta-analysis of our discovery and replication cohorts to determine association with the 49 
previously reported IBD loci implicated in adult-onset disease, determining nominal (P < 0.05) and Bonferroni-
corrected (P < 0.001, correcting for 49 hypotheses; Supplementary Table 5) significance. Of 32 previously 
confirmed loci associated with adult-onset Crohn's disease, 29 were nominally significant and 21 were 
significant after Bonferroni correction in meta-analysis of DC-CD and RC1-UC data sets. Of eight additional 
Crohn's disease loci that attained nominal significance (P < 0.05) in the previously reported majority adult-onset 
metaanalysis5, two showed significant association with early-onset Crohn's disease, namely the IL18R1-IL18RAP 
locus on 2ql2 (rs917997, P = 6.84 × 10-5, Z= 3.98) and the C-C motif chemokine (CCL) gene cluster on 17q12 
(rs991804, P = 2.31 × 10-4, Z = -3.68; Table 4). We found that 13 of 17 previously identified adult-onset 
ulcerative colitis loci showed nominal significance, and 8 were significant after Bonferroni-corrected meta-
analysis of DC-CD and RC1-UC data sets, including IL23R on lp31 and IL26 on 12ql5 (Supplementary Table 5). 
Our data also supported the association of loci on 20ql3 and 21q22 with early-onset IBD, as previously reported1 
on the basis of analyses of a subset of our discovery cohort (Supplementary Note). 
We also evaluated previously reported loci associated with adult-onset Crohn's disease for association with 
early-onset ulcerative colitis, and vice versa. Examining 32 known Crohn's disease signals in our ulcerative 
colitis cohort implicated two loci that had not previously been associated with adult-onset ulcerative colitis 
susceptibility in early-onset ulcerative colitis: ICOSLG on 2lq22 (rs762421, P = 2.54 × 10-5, Z = 4.21) and 
ORMDL3 on 17q12 (rs2872507, P = 7.62 × 10-4, Z = 3.37; Supplementary Table 5). When examining the 
association of early-onset Crohn's disease with 17 previously reported adult-onset ulcerative colitis signals, we 
detected association only with the ulcerative colitis gene IL10 on lq32.1 (rs3024505, P = 0.00048, Z = 3.49), 
suggesting that this locus may also play a role in early-onset Crohn's disease susceptibility. 
Our study adds insight into the pathogenic mechanisms mediating early-onset IBD and its close relationship with 
adult-onset disease In particular, identification of IL27 as a candidate gene for Crohn's disease susceptibility 
lends further support to the involvement of th( T-helper 17 pathway16,17 in pathogenesis of Crohn's disease, 
complementing gene discoveries in other genome scans (IL23R, STAT3 JAK2, IL12B)2'3'5. In addition, our 
discovery of five new IBD susceptibility loci through analysis of a genetically enriched early-onse disease cohort 
underscores the validity of this approach in the study of complex disease. 
 
Table 4 Newly discovered effects of previously known or suggested adult IBD risk loci in early-onset IBDa 
 CD (DC-CD, RC1-CD) 
(n= 1,925/ 7,854) 
UC (DC-UC, RC1-UC) 
(n= 844/ 7,854) 
IBD (DC-IBD, RC1) 
(n= 2,895/ 7,854) 
CDkb CDpb UCkb UCpb Band Mb Genes SNP P Z P Z P Z 
  •  lq32.1 205.01 IL10, 
IL19, 
IL20 
rs3024505 4.84 x 10-4 3.49 6.20 × 10-4 3.42 6.84 × 10-6 4.50 
 •   2ql2.1 102.44 IL18R1, 
IL18RAP 
rs917997 6.84 x 10-5 3.98 0.17 1.38 5.98 × 10-5 4.01 
 •   17ql2 29.61 CCL11, 
CCL2, 
CCL7 
rs991804 2.31 x 10-4 -3.68 2.78 × 10
-2 -2.20 6.64 × 10-5 -3.99 
•    17ql2 35.29 ORUDIS rs2872507 3.65 × 10-
4 3.56 7.62 x 10-4 3.37 3.13 × 10-6 4.66 
•    21q22.3 44.44 ICOSLG1 rs762421 3.32 × 10-7 5.10 2.54 x10 -5 4.21 3.19 × 10-10 6.29 
aListed are 5 of 49 previously identified adult-onset IBD loci that were either (1) previously nominal adult IBD signals that are verified by 
our data or (2) validated adult signals previously shown to have an effect on early-onset UC (CD) and found in our study to have an effect on 
early-onset CD (UC). bFilled circles in the first four columns of the table specify whether the given row represents a known CD locus (CDk), 
putative/nominal CD locus (CDp), known UC locus (UCk) and/or putative/nominal UC locus (UCp). Loci replicating at a Bonferroni-
corrected P < 0.05 (corrected for 49 hypotheses) are denoted in bold; newly discovered significant effects are denoted in bold italics. 
 
METHODS 
Methods and any associated references are available in the online version of the paper at 
http://www.nature.com/naturegenetics/. 
Accession codes. Gene Expression Omnibus (GEO): colonic gent expression data set, GSE10616. Entrez Gene: 
IL27, 246779; SULT1A1 171150; SULT1A2, 601292; EIF3C, 8663; HORMAD2, 150280 MTMR3, 8897; LIF, 
Published in : Nature Genetics (2009) 
Status : Postprint (Author’s version) 
159540; ZMIZ1, 57178; CAPN10,11132; GPR35 2859; KIF1A, 547; RNPEPL1, 57140. 
Note: Supplementary information is available on the Nature Genetics website. 
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ONLINE METHODS 
Participants. The early-onset IBD discovery case cohort (DC-IBD; Supplementary Table 1) consisted of 2,413 
Europeans with ancestry cases of IBD (1,636 with Crohn's disease, 724 with ulcerative colitis and 53 with IBD-
U) recruited from multiple centers from four geographically discrete countries that met the study's quality-
control criteria and were successfully matched with disease-free control subjects from the United States (see 
Supplementary Note for additional details). The Research Ethics Boards of the respective hospitals and other 
participating centers approved this study, and written informed consent was obtained from all subjects (or their 
legal guardians). 
Genotyping. We performed high-throughput genome-wide SNP genotyping using Illumina Infinium II 
HumanHap550 BeadChip technology at the Center for Applied Genomics at CHOP as described18. After 
genotyping, we excluded 270 individuals with IBD for whom >2% of genotypes were missing. Control subjects 
used for this study were also filtered to include those with a genotyping frequency of >98%. 
Population stratification. We applied the program STRUCTURE to our quality-controlled data set to exclude 
316 individuals with <95% European ancestry on the basis of ancestry informative markers19. After these 
exclusions, our cohort consisted of 2,784 IBD cases, including 1,887 Crohn's disease-only, 835 ulcerative colitis-
only and 54 IBD-U cases. Controls were filtered for 95% European ancestry, as determined by STRUCTURE, 
yielding 7,315 total subjects. 
Because of the differing geographical origins between our cases and controls, we performed PCA-based genetic 
matching (eigenmatching) to minimize intra-European population stratification. Eigenmatching uses singular 
value decomposition of genotypic data to match cases to their closest controls in the space of k principal 
components. This approach is a variant of a published method20; however in contrast to that method, we 
employed matching as a filtering criterion. Unlike EIGENSTRAT, a common approach to correct for the effects 
of stratification by adjusting genotype values, eigenmatching removes samples from both cases and controls that 
are responsible for stratification. We eigenmatched IBD cases and controls through a multistep procedure. First, 
we computed principal components for our data set by running smartpca in the EIGENSTRAT21 package on 
100,000 random autosomal SNPs. Second, we applied a matching algorithm implemented in MATLAB to the 
principal components results21. This algorithm determines a distance for each case-control pair after mapping 
each sample to coordinates on the basis of the top k eigenvalue-scaled principal components. The algorithm then 
matches each case to up to p nearby controls, keeping only cases that match between p and q controls within a 
distance d (where p, q, d and k are ι user-specified parameters). 
We genetically matched cases in the discovery cohort by using the top seven principal components, matching 
cases to three genetically related controls, and keeping cases with between one and three controls within a 
distance of 0.1. We chose k = 7 on the basis of the decay plot of the eigenvalues corresponding to the top 
principal components. We chose 0.1 as a distance threshold d after manual optimization minimizing the genomic 
inflation factor (λ) while maximizing power (that is, number of cases). After matching, we obtained λ values of 
1.13, 1.09 and 1.16 for the early-onset IBD, Crohn's disease and ulcerative colitis cohorts, respectively. Our final 
discovery cohort after matching consisted of 2,413 cases and 6,158 controls, including 1,636 Crohn's disease and 
724 ulcerative colitis cases. A summary of the number of subjects who met quality-control and genetic matching 
criteria for study inclusion is shown in Supplementary Table 1. We also performed genetic matching in the 
replication cohort. Given the smaller number of cases, we employed k = 7 principal components to match each 
case to ten genetically related controls, keeping cases with between one and ten controls within a distance of 
0.05. This yielded λ values of 1.16,1.14 and 1.08 for the IBD, Crohn's disease and ulcerative colitis replication 
cohorts, respectively. Our final replication cohort RC1 consisted of 482 early-onset IBD cases and 1,696 
controls, including 289 Crohn's disease, 120 ulcerative colitis and 73 IBD-U cases. 
Replication experiments. We assembled an early-onset IBD replication cohort (RC1) that included cases that 
were not genetically matched to controls during creation of the discovery cohort and additional cases from the 
CHOP health system that were obtained through an ongoing collection effort. Additional cases were also 
genotyped by Illumina Infinium II HumanHap550 BeadChip technology using standard approaches for quality-
control filtering (see above). Cases in RC1 were genetically matched to an independent set of European ancestry 
controls gathered from the CHOP internal collection. After genetic matching, this data set consisted of 482 early-
onset IBD cases (289 Crohn's disease, 120 ulcerative colitis and 73 IBD-U) and 1,696 controls. Subsets of data 
set RC1 corresponding to Crohn's disease and ulcerative colitis subtypes are designated as RC1-CD (n = 289) 
and RC2-UC (n = 120). 
Published in : Nature Genetics (2009) 
Status : Postprint (Author’s version) 
We used a second early-onset IBD replication cohort (RC2-CD) obtained from the IIBDGC. The IIBDGC 
replication experiment was based on data from genome-wide scans by the NIDDK10, WTCCC11 and a Belgian-
French12 collaboration that have previously been combined to undertake a large-scale meta-analysis5. Imputed 
genotype data (using HapMap II B35 r21 (CEU) as the reference population) was used when directly genotyped 
data were unavailable for a given cohort (details of the genotyping platforms used in each GWAS have been 
previously described5). In total, 531 early-onset cases (17.1% of the total IIBDGC Crohn's disease cases) and 
4,109 population controls were included in the replication effort. Mean age at onset in the IIBDGC early-onset 
cases was 14.6 yr (s.d. = 3.27 yr). Details of the ascertainment and characterization of the IIBDGC cohort, as 
well as the quality-control procedures applied to the GWAS data sets, are provided in the original scan and 
replication publications10-12,22,23. Recruitment of study subjects was approved by local and national institutional 
review boards, and informed consent was obtained from all participants. 
Lastly, we followed up select early-onset IBD signals from a meta-analysis of adult-onset Crohn's disease5, 
which combined data from three scans totaling 3,230 cases and 4,829 controls. 
Association analysis. To detect significantly associated susceptibility alleles, we compared single-marker allele 
frequencies using χ2 statistics on SNPs with a minor allele frequency of >1% and with Hardy-Weinberg 
equilibrium P > 10-5. All tests of association were carried out using PLINK24 and MATLAB with standard 
criteria for SNP quality-control filtering (see Supplementary Note). Given a conservative estimate of less than -
500,000 independent hypotheses, we determined genome-wide significance with a Bonferroni-corrected P-value 
threshold of 1.0 × 10-7. We also examined nominal signals below a P-value threshold of 1 × 10-6. We excluded 
'loner' signals whose significance level was discordant with that of adjacent SNPs in their LD or genomic 
neighborhood. SNP coordinates were obtained from the National Center for Biotechnology Information (NCBI) 
Build 36 and LD information was obtained using HapMap II B36 r27 (CEU). We used PLINK and MATLAB to 
determine nominal P values, ORs and confidence intervals for ORs for all SNPs tested. We compared our 
association results with SNPs in published data sets by using either the exact SNP or the best LD surrogate (r2 > 
0.2) found on our scan. 
We combined data from multiple scans for meta-analysis by computing a Z score at each SNP. In brief, P values 
in each scan i were transformed via the inverse normal cumulative distribution function into a Z score zi, with 
signs of the score indicating direction of effect relative to the minor allele, that is, positive Z scores for risk-
conferring variants (OR > 1) and negative Z scores for protective variants (OR < 1). Z scores zi from individual 
studies were summed into a zmeta value using weights wi for each scan computed as sqrt(Ni/N) where Ni is the 
number of individuals in study i and N is the total number of individuals across all studies. The combined Z score 
zmeta was transformed into a P value via the normal cumulative distribution function. Z scores were computed for 
299,238,489,951 and 299,238 SNPs in the Crohn's disease, ulcerative colitis and IBD meta-analyses, 
respectively. All meta-analysis computations were implemented and performed using MATLAB. 
Gene expression analysis. We examined allele-specific effects on gene expression for significantly associating 
loci by assaying total RNA in genotyped LCLs. We also compared gene expression between colonic biopsy 
specimens obtained from early-onset IBD cases and normal controls to detect disease-specific gene expression 
differences. We evaluated allele-specific effects on the expression of genes 1127 and EIF3C for the rsl968752 
variant on 16pl 1 and genes HORMAD2 and LIF for the rs2412973 variant on 21q22 (see 
Supplementary Note). In brief, RNA was isolated from Hap Map- CEU population samples using Trizol 
(Invitrogen). Real-time RT PCR was performed on a Bio-Rad iCycler System using SYBR Green detection 
(Bio-Rad). cDNA template was made from 2 µg of total RNA by using the Invitrogen cDNA Synthesis kit. 
Primer sequences were designed using Integrated DNA Technologies (IDT). β-Actin was used as a control. Each 
reaction was carried out in triplicate wells on one plate. Fold change between the A/A and C/C genotype was 
calculated with the comparative CT method. Results were normalized to β-actin for cDNA quantification. Data 
were analyzed by analysis of variance (AN OVA). We also examined allele-specific changes on gene expression 
in a publicly available LCL database14. 
We examined colonic expression of selected candidate genes located in the LD blocks of our most significant 
signals. Gene expression was assayed in individual colonic biopsy specimens from subjects with early-onset 
Crohn's disease (n = 30) and early-onset ulcerative colitis (n = 10), and from healthy controls (n = 11). 
Individuals were aged from 5 to 18 years at time of biopsy with a median age of 13 years. Inflammation was 
quantified in colon biopsies by using the Crohn's Disease Histological Index of Severity, and ranged from grade 
1 to 12 with a median of 3.5. Of the 30 individuals with Crohn's disease, 16 were receiving one or more of the 
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following medications at time of biopsy: 5-ASA, Cytoxan, 6-mercaptopurine and methotrexate. After informed 
consent, colonic biopsies were obtained from subjects with Crohn's disease and ulcerative colitis, and healthy 
controls. All of the biopsies for IBD cases and healthy controls were obtained from the ascending colon, with the 
exception of one subject with ulcerative colitis whose biopsy was obtained from the rectum. Colon biopsies were 
immediately placed in RNAlater stabilization reagent (Qiagen, Germany) at 4 °C. Total RNA was isolated by an 
RNeasy Plus Mini Kit (Qiagen) and stored at -80 °C. Samples were then submitted to the CCHMC Digestive 
Health Center Microarray Core where the quality and concentration of RNA were measured by the Agilent 
Bioanalyser 2100 (Hewlett Packard) using an RNA 6000 Nano Assay to confirm a 28S/18S ratio of 1.6-2.0. We 
amplified 100 ng of total RNA by using a Target 1-round Aminoallyl-aRNA Amplification Kit 101 (Epicentre, 
WI). The biotinylated cRNA was hybridized to Affymetrix GeneChip Human Genome HG-U133 Plus 2.0 
arrays, containing probes for 22,634 genes. The images were captured by an Affymetrix Genechip Scanner 3000. 
The complete data set is available at the NCBI Gene Expression Omnibus. Of note, this data set includes two 
additional expression profiles for two individuals with early-onset Crohn's disease who were biopsied both pre-
and posttherapy The posttherapy samples for these individuals were not used in analyses for this paper (that is, 
we used gene expression values only from pretherapy samples). Significance of gene expression changes was 
assessed by one-way ANOVA with Tukey-Kramer multiple comparison correction and P-value thresholds of P 
< 0.05, P < 0.001 and P < 0.0001. Genes demonstrating significant expression differences were further 
evaluated by one-way analysis of covariance (ANCOVA) with Tukey-Kramer multiple comparison correction 
and the same P-value thresholds, applying histological inflammation score and number of concurrent medication 
as covariates to assess the impact of these clinicopathological factors on the expression results. We also 
determined allele-specific colonic gene expression in colonic tissue for our most significantly associated SNPs. 
For this, we used a subset of IBD cases (n = 13) for which both gene expression was measured and genome-wide 
genotyping was done (as part of the current study). We determined allele-specific expression by one-way 
ANOVA with a significance threshold of 0.05. All gene expression analyses and statistical tests were 
implemented and performed in MATLAB. 
URL. GEO, http://www.ncbi.nlm.nih.gov/geo. 
